Why has Syneos Health seen a 20% decline in new contract research organization (CRO) partnerships for rare disease studies in the last 6 months?

Introduction

Syneos Health's 20% decline in new contract research organization (CRO) partnerships for rare disease studies over the last 6 months is a concerning trend that requires immediate attention. To address this issue, I'll employ a systematic approach to identify, validate, and address the root cause while considering both short-term and long-term implications.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking there might be a seasonal component. Has this 20% decline been compared to the same period last year?

Why it matters: Seasonal fluctuations could explain the decline without indicating a larger problem. Expected answer: Yes, it's been compared and is still significant. Impact on approach: If seasonal, we'd focus on cyclical strategies; if not, we'd look deeper into recent changes.

• Considering the specificity of rare disease studies, I'm wondering about the pipeline. Has there been a change in the number of rare disease drugs entering clinical trials industry-wide?

Why it matters: This could indicate an external factor affecting all CROs, not just Syneos. Expected answer: No significant change in the industry pipeline. Impact on approach: If industry-wide, we'd focus on competitive positioning; if Syneos-specific, we'd examine internal factors.

• Thinking about Syneos' competitive position, has there been any change in our pricing or service offerings for rare disease studies in the last year?

Why it matters: Changes in pricing or services could directly impact partnership decisions. Expected answer: No major changes in pricing or core services. Impact on approach: If changes occurred, we'd evaluate their impact; if not, we'd look at other internal factors.

• Considering the complexity of rare disease studies, I'm curious about our success rates. Has there been any notable change in the outcomes or timelines of our recent rare disease studies?

Why it matters: Performance issues could be deterring potential partners. Expected answer: No significant changes in success rates or timelines. Impact on approach: If performance has declined, we'd focus on operational improvements; if not, we'd explore other factors affecting partner decisions.